Prevalence of HI-PEITHO–Eligible Patients in the RIETE Registry and Simulated Population-Level Projections for Ultrasound-Facilitated Catheter-Directed Fibrinolysis

Extract Normotensive acute pulmonary embolism (PE) with right ventricular (RV) dysfunction and elevated cardiac biomarkers (ESC intermediate-high risk; AHA/ACC categories C3–D2) is associated with a substantial risk of adverse outcomes. [1, 2] Reported 7-day mortality ranges from 1–2%, while clinical deterioration requiring escalation of care occurs in approximately 5–10% of patients treated with anticoagulation alone. [3, 4] Addressing the longstanding debate regarding the optimal management of intermediate-high-risk PE, the recently published Higher-Risk Pulmonary Embolism Thrombolysis (HI-PEITHO) trial enrolled a risk-enriched cohort with features of cardiorespiratory compromise.

Authors

Institutions

Publication Details

Journal
ERJ Open Research
Published
2026-11-19
DOI
https://doi.org/10.1183/23120541.01273-2026
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prevalence of HI-PEITHO–Eligible Patients in the RIETE Registry and Simulated Population-Level Projections for Ultrasound-Facilitated Catheter-Directed Fibrinolysis

Pablo Demelo‐Rodríguez, Sina Rashedi, Romain Chopard, Samuel Zachary Goldhaber et al.
ERJ Open Research
Venous Thromboembolism Diagnosis and Management
article

Prevalence of HI-PEITHO–Eligible Patients in the RIETE Registry and Simulated Population-Level Projections for Ultrasound-Facilitated Catheter-Directed Fibrinolysis

Pablo Demelo‐Rodríguez, Sina Rashedi, Romain Chopard, Samuel Zachary Goldhaber, Behnood Bikdeli, the RIETE investigators, Gregory Piazza, Manuel Monréal, Adriana González-Munera, Mariana Becker Pfeferman, Carmine Siniscalchi
article en

Abstract

Extract Normotensive acute pulmonary embolism (PE) with right ventricular (RV) dysfunction and elevated cardiac biomarkers (ESC intermediate-high risk; AHA/ACC categories C3–D2) is associated with a substantial risk of adverse outcomes. [1, 2] Reported 7-day mortality ranges from 1–2%, while clinical deterioration requiring escalation of care occurs in approximately 5–10% of patients treated with anticoagulation alone. [3, 4] Addressing the longstanding debate regarding the optimal management of intermediate-high-risk PE, the recently published Higher-Risk Pulmonary Embolism Thrombolysis (HI-PEITHO) trial enrolled a risk-enriched cohort with features of cardiorespiratory compromise.

ERJ Open Research
University of Parma (IT), Brigham and Women's Hospital (US), Yale New Haven Hospital (US), Harvard University (US), Hospital General Universitario Gregorio Marañón (ES), Centre Hospitalier Universitaire de Besançon (FR)
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon